Skip to main content

Biosite Partners with Neurocrine Biosciences in Antibody, Stroke Target Collaboration

NEW YORK, Feb. 20 - Biosite and Neurocrine Biosciences have signed a three-year research collaboration, the companies said today.


Under the agreement, Neurocrine will provide drug targets, and Biosite will use its phage display technology to generate antibodies to the targets. Biosite will get fees for antibodies when it delivers them to Neurocrine, as well as possible milestone fees, and diagnostic licenses to stroke targets to which Neurocrine has rights. Neurocrine will use the antibodies in its drug discovery research.


Biosite, which focuses on protein-based diagnostics, also has an antibody discovery collaboration agreement with Ciphergen and an agreement to developing protein chips with Large Scale Biology.


For more information on this collaboration, see the company statement.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.